FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso · Senolytic Peptide · Proxofim
A senolytic peptide that selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, effectively clearing 'zombie cells' that drive aging.
Overview
FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells — often called 'zombie cells' — that accumulate with age and drive chronic inflammation, tissue dysfunction, and age-related disease. Senescent cells resist normal apoptosis (programmed cell death) by maintaining a survival interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein. FOXO4-DRI is engineered to disrupt this specific interaction, releasing p53 from FOXO4 sequestration and allowing it to trigger apoptosis selectively in senescent cells. Healthy cells, which do not depend on the FOXO4-p53 interaction for survival, are unaffected.
In groundbreaking research published in Cell, FOXO4-DRI treatment in aged mice restored fitness, fur density, and renal function — essentially reversing aspects of aging. This represents one of the most targeted senolytic approaches available.
Mechanism of Action
A D-retro-inverso peptide that competitively disrupts the FOXO4-p53 protein-protein interaction in senescent cells. When FOXO4 is displaced from p53, p53 is released to the mitochondria where it triggers intrinsic apoptosis specifically in senescent cells. The D-amino acid retro-inverso design provides protease resistance and enhanced cellular penetration.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for FOXO4-DRI. Always consult a healthcare professional before combining compounds.
Synergistic (1)
FOXO4-DRI is a senolytic (clears senescent cells) while rapamycin inhibits mTOR to slow cellular aging. Complementary: clear damaged cells + slow aging of remaining cells.
Scientific References
Quick Reference
Typical Dose
5mg
Frequency
1x daily
Route
Subcutaneous injection
Half-Life
~12-24 hours (D-amino acids resist proteolysis)
Cycle Length
3 days on, followed by 2-6 months recovery
FDA Status
Research compound — not FDA approved. Preclinical data published in Cell (2017).
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.
Related Peptides in Longevity & Anti-Aging
Metformin
The world's most prescribed diabetes medication, now studied as a potential anti-aging drug through AMPK activation, mTOR inhibition, and mitochondrial effects.
Read moreRapamycin
The only compound proven to extend lifespan in every organism tested, from yeast to mammals, through inhibition of the mTOR pathway — the master regulator of cellular aging.
Read moreNAD+ / NMN
NAD+ precursors that restore declining cellular energy levels, activate sirtuins and PARPs, and support DNA repair — central to the biology of aging.
Read more